Luminal B breast tumors are not HER2 positive.
作者信息
Bhargava Rohit, Dabbs David J
出版信息
Breast Cancer Res. 2008;10(5):404; author reply 405. doi: 10.1186/bcr2134. Epub 2008 Sep 26.
Abstract
摘要
相似文献
1
Luminal B breast tumors are not HER2 positive.
Breast Cancer Res. 2008;10(5):404; author reply 405. doi: 10.1186/bcr2134. Epub 2008 Sep 26.
2
HER2 as a prognostic factor in breast cancer.
Oncology. 2001;61 Suppl 2:67-72. doi: 10.1159/000055404.
3
4
Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
West Indian Med J. 2002 Mar;51(1):4-9.
5
Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
J Exp Clin Cancer Res. 1999 Sep;18(3):357-61.
6
Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Arch Gynecol Obstet. 2009 Jul;280(1):43-8. doi: 10.1007/s00404-008-0867-1. Epub 2008 Dec 11.
7
Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
Mod Pathol. 2001 Mar;14(3):263. doi: 10.1038/modpathol.3880297.
8
[Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
Ginecol Obstet Mex. 2006 Oct;74(10):516-22.
9
The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
Mod Pathol. 2000 Jan;13(1):1-3. doi: 10.1038/modpathol.3880001.
10
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Histopathology. 2006 May;48(6):702-7. doi: 10.1111/j.1365-2559.2006.02403.x.
引用本文的文献
1
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer.
Mol Cancer Ther. 2020 Jan;19(1):3-12. doi: 10.1158/1535-7163.MCT-19-0253.
2
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.
J Cancer Epidemiol. 2014;2014:469251. doi: 10.1155/2014/469251. Epub 2014 May 26.
3
Hypothesized role of pregnancy hormones on HER2+ breast tumor development.
Breast Cancer Res Treat. 2013 Jan;137(1):237-46. doi: 10.1007/s10549-012-2313-0. Epub 2012 Nov 8.
4
A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy.
Int J Breast Cancer. 2011;2011:217060. doi: 10.4061/2011/217060. Epub 2011 Aug 17.
5
Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.
Breast Cancer (Auckl). 2012;6:1-8. doi: 10.4137/BCBCR.S8323. Epub 2011 Dec 6.
6
Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
Med Oncol. 2012 Sep;29(3):1536-42. doi: 10.1007/s12032-011-0082-y. Epub 2011 Oct 8.
7
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
BMC Cancer. 2011 Jul 12;11:292. doi: 10.1186/1471-2407-11-292.
本文引用的文献
1
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.
Breast Cancer Res. 2008;10(4):R67. doi: 10.1186/bcr2128. Epub 2008 Aug 5.
2
Histopathologic variables predict Oncotype DX recurrence score.
Mod Pathol. 2008 Oct;21(10):1255-61. doi: 10.1038/modpathol.2008.54.
3
Molecular classification of breast tumors: toward improved diagnostics and treatments.
Methods Mol Biol. 2007;360:91-114. doi: 10.1385/1-59745-165-7:91.
4
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
JAMA. 2006 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492.
5
HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
Am J Clin Pathol. 2004 May;121(5):631-6. doi: 10.1309/VE78-62V2-646B-R6EX.
6
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.
Am J Pathol. 2004 Jan;164(1):35-42. doi: 10.1016/S0002-9440(10)63093-3.
7
Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.
Am J Clin Pathol. 2003 Jul;120(1):86-92. doi: 10.1309/QPHD-RB00-QXGM-UQ9N.
8
Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison.
Breast Cancer Res Treat. 2001 Jun;67(3):263-71. doi: 10.1023/a:1017946810277.
9
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. doi: 10.1073/pnas.191367098.
10
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J Clin Oncol. 1999 May;17(5):1474-81. doi: 10.1200/JCO.1999.17.5.1474.
Zotero 插件